CoChat

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

Open access
Bendell, J., Ciardiello, F., Tabernero, J., Tebbutt, N., Eng, C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N., Sobrero, A., Shi, Y., Roberts, L., Yan, Y., Chang, I., Uyei, A., Kim, T. · 2018 · Annals of Oncology
Cited by 50

The DOI matches its Crossref record.

Abstract

Background: Patients with chemotherapy-refractory microsatellite stable (MSS) metastatic colorectal cancer (CRC) are a population with limited treatment options and relatively short survival. Atezolizumab (an anti–PD-L1 mAb) inhibits the binding of PD-L1 to its receptors PD-1 and B7.1, leading to the re-invigoration of tumour-specific T-cell immunity. Cobimetinib inhibits MEK1/MEK2 in the MAPK pathway, and blocking the MAPK pathway has been shown to favourably alter the tumour, tumour microenvironment and T-cell responses to promote anti-tumour immune activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy208.003

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 50

Metadata

Authors
Bendell, J., Ciardiello, F., Tabernero, J., Tebbutt, N., Eng, C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N., Sobrero, A., Shi, Y., Roberts, L., Yan, Y., Chang, I., Uyei, A., & Kim, T.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-06
Volume
29
Pages
v123
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2811494160
Cited by
50
References
0
FWCI
3.54
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. https://app.cochat.ai/papers/10.1093/annonc/mdy208.003
The paper
Bendell, J., Ciardiello, F., Tabernero, J., Tebbutt, N., Eng, C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N., Sobrero, A., Shi, Y., Roberts, L., Yan, Y., Chang, I., Uyei, A., & Kim, T. (2018). Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdy208.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.